Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 1Osteoporosis, Postmenopausal 1Neoplasms 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × LY 353381 × Clear all
NCT00005879 2017-05-30

LY353381 in Preventing Breast Cancer in Women With Hyperplasia

University of Kansas Medical Center

Phase 2 Completed
199 enrolled 16 charts
Breast

Breast Neoplasms

NCT00088010 2010-06-02

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

Eli Lilly and Company

Phase 3 Completed
9,369 enrolled

Osteoporosis, Postmenopausal

NCT00190697 2007-05-25

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Eli Lilly and Company

Phase 4 Completed
70 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00034125 2006-07-19

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Eli Lilly and Company

Phase 3 Completed
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡